FAB.L
Fusion Antibodies PLC
Price:  
4.24 
GBP
Volume:  
256,537.00
United Kingdom | Life Sciences Tools & Services
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

FAB.L EV/EBITDA

-416.2%
Upside

As of 2026-11-16, the EV/EBITDA ratio of Fusion Antibodies PLC (FAB.L) is -5.17. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FAB.L's latest enterprise value is 7.33 mil GBP. FAB.L's TTM EBITDA according to its financial statements is -1.42 mil GBP. Dividing these 2 quantities gives us the above FAB.L EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 11.0x - 24.7x 18.6x
Forward P/E multiples 10.8x - 16.5x 13.4x
Fair Price (9.26) - (13.82) (13.39)
Upside -318.6% - -426.2% -416.2%
4.24 GBP
Stock Price
(13.39) GBP
Fair Price

FAB.L EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2026-11-13 -5.27
2026-11-12 -5.21
2026-11-11 -5.22
2026-11-10 -5.24
2026-11-09 -6.15
2026-11-06 -6.48
2026-11-05 -7.01
2026-11-04 -7.02
2026-11-03 -7.33
2026-11-02 -7.35
2026-10-30 -7.38
2026-10-29 -7.73
2026-10-28 -7.62
2026-10-27 -6.73
2026-10-26 -6.75
2026-10-23 -6.78
2026-10-22 -7.01
2026-10-21 -7.02
2026-10-20 -7.33
2026-10-19 -7.35
2026-10-16 -7.92
2026-10-15 -7.37
2026-10-14 -11.82
2026-10-13 -11.83
2026-10-12 -11.84
2026-10-09 -12.18
2026-10-08 -12.10
2026-10-07 -12.12
2026-10-06 -12.43
2026-10-05 -13.64
2026-10-02 -13.67
2026-10-01 -13.90
2026-09-30 -13.91
2026-09-29 -14.52
2026-09-28 -15.14
2026-09-25 -14.27
2026-09-24 -14.50
2026-09-23 -13.55
2026-09-22 -13.57
2026-09-21 -13.64
2026-09-18 -13.37
2026-09-17 -13.00
2026-09-16 -13.61
2026-09-15 -13.03
2026-09-14 -11.24
2026-09-11 -14.27
2026-09-10 -13.90
2026-09-09 -13.61
2026-09-08 -13.93
2026-09-07 -13.94